Payment overview · 2025
General Payments
$1,881.50
116 reported records · 22 companies
Healthcare provider profile · identity verified
Allison Lee Kovar, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · ONAWA, IA · NPI 1942468111
Verified facts
What the public records show
CMS Open Payments records show Allison Lee Kovar, M.D. received $1,881.50 in general payments during 2025 across 116 reported records.
ABBVIE INC. accounted for 24.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 37 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Gemtesa, Jardiance, Kerendia, Linzess, Ozempic, Prolia, Rexulti, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Prolia by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Kerendia by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 156 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Jardiance by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 156 claims for Eliquis by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $468.89 | 24.9% | 35 | 2025 |
| W. L. Gore & Associates, Inc. | Unresolved — no canonical attribution shown | $231.42 | 12.3% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $148.32 | 7.9% | 14 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $144.75 | 7.7% | 10 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $100.77 | 5.4% | 6 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $94.89 | 5.0% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $86.53 | 4.6% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $75.77 | 4.0% | 5 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $69.12 | 3.7% | 6 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $68.74 | 3.6% | 4 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $65.54 | 3.5% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $53.71 | 2.9% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $52.18 | 2.8% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $50.12 | 2.7% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $37.31 | 2.0% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $28.13 | 1.5% | 2 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $21.76 | 1.2% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $18.56 | 1.0% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $18.45 | 1.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.48 | 0.9% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $15.27 | 0.8% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $13.79 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,871.15 | 115 |
| Travel and Lodging | $10.35 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $224.46 | 21 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $152.80 | 9 | 2025 |
Source payment records
|
|||||
| GORE SYNECOR Biomaterial Normalized: gore synecor biomaterial |
Device | W. L. Gore & Associates, Inc. | $133.19 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $115.39 | 11 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $111.50 | 7 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $103.83 | 6 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $100.77 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $100.49 | 7 | 2025 |
Source payment records
|
|||||
| Product in Development Normalized: product in development |
Device | W. L. Gore & Associates, Inc. | $98.23 | 1 | 2025 |
Source payment records
|
|||||
| DALVANCE Normalized: dalvance |
Drug | ABBVIE INC. | $82.27 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $75.77 | 5 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $69.12 | 6 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $68.74 | 4 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $65.54 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $61.68 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $52.18 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $45.31 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $45.31 | 3 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $39.74 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $37.31 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $32.93 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $29.77 | 2 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $28.13 | 2 | 2025 |
Source payment records
|
|||||
| TEFLARO Normalized: teflaro |
Drug | ABBVIE INC. | $24.66 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $24.16 | 2 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $21.76 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $21.76 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $21.47 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $19.78 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $18.56 | 1 | 2025 |
Source payment records
|
|||||
| CERDELGA Normalized: cerdelga |
Drug | GENZYME CORPORATION | $18.45 | 1 | 2025 |
Source payment records
|
|||||
| FABRAZYME Normalized: fabrazyme |
Biological | GENZYME CORPORATION | $18.45 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $17.48 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $16.05 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $15.27 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $14.09 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $13.79 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 156 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 39 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 81 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 15 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 70 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
15 | 11 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
156 | 27 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
63 | 63 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
26 | 22 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
107 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
70 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
81 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
70 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
156 | 27 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 376 | 62 |
| Atorvastatin Calcium | Atorvastatin Calcium | 372 | 73 |
| Omeprazole | Omeprazole | 314 | 70 |
| Amlodipine Besylate | Amlodipine Besylate | 275 | 56 |
| Metoprolol Succinate | Metoprolol Succinate | 225 | 52 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 223 | 49 |
| Furosemide | Furosemide | 219 | 48 |
| Lisinopril | Lisinopril | 186 | 46 |
| Sertraline Hcl | Sertraline Hcl | 184 | 32 |
| Potassium Chloride | Potassium Chloride | 165 | 36 |
| Eliquis | Apixaban | 156 | 27 |
| Tramadol Hcl | Tramadol Hcl | 147 | 45 |
| Gabapentin | Gabapentin | 142 | 28 |
| Pantoprazole Sodium | Pantoprazole Sodium | 132 | 25 |
| Losartan Potassium | Losartan Potassium | 129 | 35 |
| Meloxicam | Meloxicam | 125 | 36 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 115 | 35 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 107 | 22 |
| Montelukast Sodium | Montelukast Sodium | 87 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 86 | 30 |
| Alprazolam | Alprazolam | 83 | 28 |
| Bupropion Xl | Bupropion Hcl | 81 | 14 |
| Ozempic | Semaglutide | 81 | 15 |
| Famotidine | Famotidine | 79 | 13 |
| Cefdinir | Cefdinir | 76 | 62 |
| Prednisone | Prednisone | 74 | 54 |
| Trazodone Hcl | Trazodone Hcl | 71 | 21 |
| Rexulti | Brexpiprazole | 70 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 68 | 13 |
| Metformin Hcl | Metformin Hcl | 68 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 67 | 13 |
| Donepezil Hcl | Donepezil Hcl | 65 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 65 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 64 | 16 |
| Tamsulosin Hcl | Tamsulosin Hcl | 64 | 15 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 63 | 63 |
| Clopidogrel | Clopidogrel Bisulfate | 63 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 59 | 16 |
| Bumetanide | Bumetanide | 58 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 58 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 56 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 53 | 13 |
| Lorazepam | Lorazepam | 52 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 52 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 50 | 24 |
| Carvedilol | Carvedilol | 47 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 46 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 46 | suppressed |
| Xarelto | Rivaroxaban | 45 | suppressed |
| Pregabalin | Pregabalin | 44 | suppressed |
| Azithromycin | Azithromycin | 43 | 34 |
| Ezetimibe | Ezetimibe | 43 | suppressed |
| Simvastatin | Simvastatin | 43 | 11 |
| Levofloxacin | Levofloxacin | 42 | 33 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 42 | suppressed |
| Gemtesa | Vibegron | 40 | suppressed |
| Kerendia | Finerenone | 39 | suppressed |
| Spironolactone | Spironolactone | 38 | suppressed |
| Levetiracetam | Levetiracetam | 37 | suppressed |
| Atenolol | Atenolol | 36 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 36 | suppressed |
| Rybelsus | Semaglutide | 36 | suppressed |
| Mirtazapine | Mirtazapine | 34 | suppressed |
| Febuxostat | Febuxostat | 33 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 33 | 27 |
| Allopurinol | Allopurinol | 32 | 11 |
| Memantine Hcl | Memantine Hcl | 32 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 30 | suppressed |
| Finasteride | Finasteride | 29 | suppressed |
| Jardiance | Empagliflozin | 29 | suppressed |
| Myrbetriq | Mirabegron | 29 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 28 | suppressed |
| Risperidone | Risperidone | 28 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 27 | 21 |
| Celecoxib | Celecoxib | 27 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 27 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 27 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 26 | suppressed |
| Estradiol | Estradiol | 26 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 26 | 22 |
| Sucralfate | Sucralfate | 25 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 19 |
| Alendronate Sodium | Alendronate Sodium | 24 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 24 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 24 | 11 |
| Tresiba Flextouch U-200 | Insulin Degludec | 24 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 23 | suppressed |
| Synthroid | Levothyroxine Sodium | 23 | suppressed |
| Glimepiride | Glimepiride | 22 | suppressed |
| Nystatin | Nystatin | 22 | 13 |
| Promethazine Hcl | Promethazine Hcl | 21 | suppressed |
| Amoxicillin | Amoxicillin | 20 | 13 |
| Aripiprazole | Aripiprazole | 20 | suppressed |
| Fluconazole | Fluconazole | 20 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 15 |
| Oxycodone Hcl | Oxycodone Hcl | 19 | suppressed |
| Linzess | Linaclotide | 18 | suppressed |
| Metolazone | Metolazone | 18 | suppressed |
| Nifedipine Er | Nifedipine | 18 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 17 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 17 | 11 |
| Glipizide Er | Glipizide | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 17 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 16 | suppressed |
| Loperamide | Loperamide Hcl | 16 | suppressed |
| Methylprednisolone | Methylprednisolone | 16 | 16 |
| Baclofen | Baclofen | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | 11 |
| Prolia | Denosumab | 15 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 15 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 14 | 14 |
| Carbamazepine | Carbamazepine | 14 | suppressed |
| Dasetta | Norethindrone-Ethin. Estradiol | 14 | suppressed |
| Diazepam | Diazepam | 14 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Lubiprostone | Lubiprostone | 14 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 13 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 11 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Azathioprine | Azathioprine | 11 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Oxycontin | Oxycodone Hcl | 11 | suppressed |
| Praluent Pen | Alirocumab | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,881.50 · 116 records | ABBVIE INC. | AUSTEDO XR, BEXSERO, CAMZYOS, CAPLYTA, CERDELGA, DALVANCE, ELIQUIS, EVENITY, FABRAZYME, Fluad, Flucelvax, GEMTESA, GORE SYNECOR Biomaterial, JARDIANCE, Kerendia, LEQVIO, LINZESS, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PROLIA, Product in Development, QULIPTA, REPATHA, REXULTI, Rybelsus, TEFLARO, TRINTELLIX, UBRELVY, VOQUEZNA, VRAYLAR, Veozah, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND | 17 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error